{
    "clinical_study": {
        "@rank": "144535", 
        "arm_group": [
            {
                "arm_group_label": "Low dose naltrexone", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this arm will recieve a placebo daily for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will be looking at the efficacy of the use of once daily use of low dose\n      naltrexone (4.5mg) in subjects with symptomatic inflammatory bowel disease."
        }, 
        "brief_title": "Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Inflammatory Bowel Disease", 
            "Crohn's Disease", 
            "Ulcerative Colitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators will compare the use of daily low dose naltrexone (LDN) (4.5 mg) compared\n      with placebo in subjects that have symptomatic inflammatory bowel disease (IBD). Our\n      subjects will be those with diagnosed with IBD and are symptomatic, defined by an\n      inflammatory bowel disease questionnaire (IBDQ) score < 170. The subjects will be randomly\n      assigned either placebo or LDN. They will take the IBDQ prior to starting the trial, 6\n      weeks, 12 weeks and 6 months after starting the medication. Participants have to remain on\n      their current IBD regimen throughout the trial and cannot make any changes within 4 weeks of\n      starting the trial. The investigators will have a safety phone call at 6 weeks and a follow\n      up letter at 12 weeks after starting the trial. The participants will be given a card to\n      keep with them with a phone number and email address if any adverse effects arise."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with symptomatic Crohn's disease or ulcerative colitis (defined as a\n             response to the Inflammatory Bowel Disease Questionnaire less than 170)\n\n          -  Confirmed Crohn's disease or ulcerative colitis through radiographic, endoscopic\n             and/or histologic criteria\n\n          -  On a stable dose of medication for IBD (i.e. no change in medication within 4 weeks\n             of study enrollment)\n\n          -  Age 18 or older\n\n        Exclusion Criteria:\n\n          -  Patients on opioids or immodium within 7 days of starting the investigational therapy\n\n          -  Women who are breastfeeding, pregnant, or plan on becoming pregnant within the next\n             year\n\n          -  Patients on Lomotil or opioid analgesics\n\n          -  Patients already on low dose naltrexone\n\n          -  Women of child bearing age not willing to use contraception or abstinence\n\n          -  A history of the following diseases or procedures:\n\n               -  Acute hepatitis\n\n               -  Liver failure\n\n               -  Ileoanal anastomosis\n\n               -  Short bowel syndrome\n\n               -  Abnormal liver enzymes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810185", 
            "org_study_id": "LDN in IBD", 
            "secondary_id": "SBCH- LDN in IBD"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low dose naltrexone", 
                "description": "4.5 mg daily for 12 weeeks", 
                "intervention_name": "Low dose naltrexone", 
                "intervention_type": "Drug", 
                "other_name": "Naltrexone"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Inflammatory Bowel Disease", 
            "Crohn's disease", 
            "Ulcerative colitis", 
            "Naltrexone", 
            "Low Dose Naltrexone", 
            "Inflammatory Bowel Disease Questionnaire"
        ], 
        "lastchanged_date": "March 12, 2013", 
        "location": {
            "contact": {
                "email": "eimbertson@yahoo.com", 
                "last_name": "Erick J Imbertson, M.D.", 
                "phone": "925-699-5083"
            }, 
            "facility": {
                "address": {
                    "city": "Santa Barbara", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "93105"
                }, 
                "name": "Santa Barbara Cottage Hospital"
            }, 
            "investigator": {
                "last_name": "Erick J Imbertson, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease", 
        "overall_contact": {
            "email": "eimbertson@yahoo.com", 
            "last_name": "Erick J Imbertson, M.D.", 
            "phone": "(925)699-5083"
        }, 
        "overall_contact_backup": {
            "email": "syim@sbch.org", 
            "last_name": "Samantha Yim, R.N.", 
            "phone": "(805) 569-7461"
        }, 
        "overall_official": {
            "affiliation": "Santa Barabara Cottage Hospital", 
            "last_name": "Erick J Imbertson, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will fill-out a questionnaire called the IBDQ at enrollment, 6 weeks, 12 weeks, and 6 months after enrollment. The IBDQ is a validated instrument often used in routine care and studies of patients with IBD (Appendix E). The IBDQ measures the activity of IBD and quality of life. It includes 32 questions placed into 4 domains: bowel, social, emotional and systemic. Each question is ranked from 1-7, 1 being the poorest quality of life and 7 being the best quality of life8.  A score of >170 means that a patient is clinically in remission and an increase in score between 16 and 32 are considered a meaningful improvement in symptoms.", 
            "measure": "An increase in the subjects inflammatory bowel disease questionnaire score", 
            "safety_issue": "No", 
            "time_frame": "6 weeks, 12 weeks, and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810185"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Santa Barbara Cottage Hospital", 
            "investigator_full_name": "Erick Jordan Imbertson", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "17222320", 
                "citation": "Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11."
            }, 
            {
                "PMID": "23188075", 
                "citation": "Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn's Disease: A Pilot Study. J Clin Gastroenterol. 2012 Dec 13. [Epub ahead of print]"
            }, 
            {
                "PMID": "21991594", 
                "citation": "Low-dose naltrexone: tricking the body to heal itself. Exp Biol Med (Maywood). 2011 Sep;236(9):vii-viii."
            }
        ], 
        "source": "Santa Barbara Cottage Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santa Barbara Cottage Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}